A Study of EMB-02 in Participants With Advanced Solid Tumors

Inclusion Criteria: * Willing and able to provide written informed consent. * Phase I: Patients with histologically or cytologically confirmed locally advanced/metastatic solid tumors and have failed (progressed on, or are intolerant of) standard therapies. Moreover, the disease should be measurable or evaluable per RECIST v1.1 * Phase II Cohort A: Patients with histologically or cytologically confirmed locally advanced/metastatic melanoma, excluding uveal melanoma. \> 1 prior therapy, including prior treatment with PD-1/L1(mandatory) and/or CTLA-4 inhibitors(optional). And the disease is measurable or evaluable per RECIST v1.1 * Archival tumor samples available for retrospective analysis or biopsy will be taken. * ECOG performance status 0 or 1 for phase I, and ≤2 for phase II; life expectancy \> 3 Months * Adequate organ function to participate in the trial. * Recovery from adverse events (AEs) related to prior anticancer therapy. * Highly effective contraception Exclusion Criteria: * Patients who have active autoimmune disease or history of autoimmune disease * History of severe irAE. * History of severe allergic reactions * Use of systemic corticosteroids. * Symptomatic central nervous system metastases. * Patients with cardiac dysfunction * Uncontrolled diabetes mellitus with hemoglobin A1c \> 8% (via medical history) * Prior treatment with a LAG-3 inhibitor * Anticancer therapy or radiation \< 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment; * Prior organ or stem cell/bone marrow transplant. * Concurrent malignancy \< 5 years prior to entry. * Patients with active infections. * Major surgery \< 4 weeks or minor surgery \< 2 weeks prior to study treatment * Live virus vaccines \< 30 days prior to screening * Pregnant or breast-feeding females * Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment * Any other serious underlying medical conditions * Abuse on alcohol, cannabis- derived products or other drugs